Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines

Martin Bøgsted; Johanne Marie Holst; Kirsten Fogd; Steffen Falgreen Larsen; Suzette Sørensen; Alexander Schmitz; Anne Bukh; Hans Erik Johnsen; Mette Nyegaard; Karen Dybkær

doi:10.1371/journal.pone.0019322

Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines

Martin Bøgsted, Johanne Marie Holst, Kirsten Fogd, Steffen Falgreen Larsen, Suzette Sørensen, Alexander Schmitz, Anne Bukh, Hans Erik Johnsen, Mette Nyegaard, Karen Dybkær

Research output: Contribution to journal › Journal article › Research › peer-review

17 Citations (Scopus)

Abstract

Recent reports indicate that in vitro drug screens combined with gene expression profiles (GEP) of cancer cell lines may generate informative signatures predicting the clinical outcome of chemotherapy. In multiple myeloma (MM) a range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan. Consequently, the generation of predictive signatures for response to melphalan may have a clinical impact. The hypothesis is that melphalan screens and GEPs of B-cell cancer cell lines combined with multivariate statistics may provide predictive clinical information.

Original language	English
Volume	6
Pages (from-to)	e19322
Number of pages	9
ISSN	1932-6203
DOIs	https://doi.org/10.1371/journal.pone.0019322
Publication status	Published - 1 Jan 2011
Externally published	Yes

Access to Document

10.1371/journal.pone.0019322

AUB Link

Search for the material in Aalborg University Library's search engine

Cite this

@article{0d5845a44a724da2b58d84c950602fe7,

title = "Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines",

abstract = "Recent reports indicate that in vitro drug screens combined with gene expression profiles (GEP) of cancer cell lines may generate informative signatures predicting the clinical outcome of chemotherapy. In multiple myeloma (MM) a range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan. Consequently, the generation of predictive signatures for response to melphalan may have a clinical impact. The hypothesis is that melphalan screens and GEPs of B-cell cancer cell lines combined with multivariate statistics may provide predictive clinical information.",

author = "Martin B{\o}gsted and Holst, {Johanne Marie} and Kirsten Fogd and Larsen, {Steffen Falgreen} and Suzette S{\o}rensen and Alexander Schmitz and Anne Bukh and Johnsen, {Hans Erik} and Mette Nyegaard and Karen Dybk{\ae}r",

year = "2011",

month = jan,

day = "1",

doi = "10.1371/journal.pone.0019322",

language = "English",

volume = "6",

pages = "e19322",

issn = "1932-6203",

publisher = "Public Library of Science",

}

TY - JOUR

T1 - Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines

AU - Bøgsted, Martin

AU - Holst, Johanne Marie

AU - Fogd, Kirsten

AU - Larsen, Steffen Falgreen

AU - Sørensen, Suzette

AU - Schmitz, Alexander

AU - Bukh, Anne

AU - Johnsen, Hans Erik

AU - Nyegaard, Mette

AU - Dybkær, Karen

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Recent reports indicate that in vitro drug screens combined with gene expression profiles (GEP) of cancer cell lines may generate informative signatures predicting the clinical outcome of chemotherapy. In multiple myeloma (MM) a range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan. Consequently, the generation of predictive signatures for response to melphalan may have a clinical impact. The hypothesis is that melphalan screens and GEPs of B-cell cancer cell lines combined with multivariate statistics may provide predictive clinical information.

AB - Recent reports indicate that in vitro drug screens combined with gene expression profiles (GEP) of cancer cell lines may generate informative signatures predicting the clinical outcome of chemotherapy. In multiple myeloma (MM) a range of new drugs have been introduced and now challenge conventional therapy including high dose melphalan. Consequently, the generation of predictive signatures for response to melphalan may have a clinical impact. The hypothesis is that melphalan screens and GEPs of B-cell cancer cell lines combined with multivariate statistics may provide predictive clinical information.

U2 - 10.1371/journal.pone.0019322

DO - 10.1371/journal.pone.0019322

M3 - Journal article

SN - 1932-6203

VL - 6

SP - e19322

ER -

Generation of a predictive melphalan resistance index by drug screen of B-cell cancer cell lines

Abstract

Access to Document

AUB Link

Fingerprint

Cite this